A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

After running up against a roadblock earlier this summer, the controversial BIOSECURE Act could gain new momentum next week.

AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud ...

Even though dementia is widespread—with more than 55 million people around the world currently affected and 10 million new ...

After years of documentation and industry neglect, the World Health Organization (WHO) issued its first-ever guidance aimed ...

After handing over $30 million in criminal penalties last summer, Glenmark Pharmaceuticals has agreed to settle with the U.S.

With dwindling funds after a prior snub from the FDA, ImmunityBio’s journey to bag approval for its Merck-rivaling bladder ...

It’s as you were at the top of the TV drug ad spending table as AbbVie continues its 2024 domination as total spending across ...

BeiGene signed up to be the “national presenting sponsor of survivorship and hope” earlier this year. The three-year deal put ...

By adding $1.1 billion to its settlement proposal, Johnson & Johnson is inching closer to resolving approximately 62,000 personal injury lawsuits from those who claim their cancers were caused by the ...

In his nine months as CEO, BioMarin’s new chief Alexander Hardy has so far overseen shakeups in the company’s leadership team ...

Novartis is investing more than $200 million to further bolster its radiotherapy infrastructure with a brand-new facility and ...